Hormonal Control of Cancer by J A Strong MBE FRCP (Western General Hospital, and Department ofMedicine, University ofEdinburgh) From the broad terms of my remit I have chosen arbitrarily certain topics for discussion, although my personal experience of some of these is necessarily restricted.
Numerous procedures developed in recent years for the treatment of hormone-responsive tumours remain in use, though the precise indications for each are still far from clear. I shall review some of these methods, in principle rather than in detail, and examine their growing points, if they seem to have any.
Carcinoma of the breast and the prostate together provide the bulk of the problem. Thyroid cancer merits some reference, and the uses of corticosteroids in the reticuloses have been dealt with earlier. Finally, in the reproductive tract, some measure of control of uterine cancer with hormones or their synthetic analogues has been reported, and calls for comment.
CANCER OF THE BREAST
Oophorectomy Breast cancer, because of its frequency, and particularly on account of the relative youth of many of the patients, remains the most important of these diseases. Of the many forms of hormone therapy known to have some value, there is general agreement that, considered in isolation, the most useful procedure in this disease is oophorectomy, in the premenopausal patient. In addition to its immediate effect on the disease, the operation provides a useful though not infallible guide to the responsiveness or otherwise of the tumour, and thus to the effect that might be expected with further hormone treatment when, as inevitably occurs, even the responsive tumour deteriorates once more.
Prophylactic use of Oophorectomy
While the value of oophorectomy in the management of recurrent or metastatic disease is well established, the problem of prophylactic ovarian ablation is much more controversial. Paterson & Russell (1959) were unable to demonstrate a clear advantage for ovarian irradiation among nearly 750 premenopausal, menopausal and early (<two year) postmenopausal patients, although the trend was in favour of the irradiated group. It would be of interest to know whether the premenopausal group if taken alone would have shown a different result. Perhaps an other-wise significant finding was diluted out by the menopausal and postmenopausal patients included in the evaluation.
Important studies related to this problem at present in progress in Oslo have been described by Nissen-Meyer (1963) . He emphasized the concept of the 'free interval', namely the period elapsing between the initial treatment of the disease, and the subsequent appearance of metastases or local recurrence. In the premenopausal group of patients, the trend of events again appears to be in favour of ovarian ablation, that is, in increasing the length of the free interval. A more remarkable finding, however, was made in a group of 187 postmenopausal patients aged up to 70 years, and divided in a random manner into control and treated groups, in whom the results were so clearly in favour of ovarian ablation that this part of the trial could be terminated. The data showed that the differences between the groups were largely due to factors appearing within the first year after the initial treatment, but that in terms of prognosis there was little to choose between the two groups in the second and subsequent years.
Some further striking findings are emerging from this work. It was shown for example that in each five-year age group of patients up to 65-70 years, the urinary output of a single cestrogen, cestrone, was lower in the treated than in the control group, thus adding weighty evidence to other studies indicating that the postmenopausal ovary may still be capable of secretory activity, even if it is no longer producing gametes.
Corticosteroid Therapy
Nissen-Meyer has long been an advocate of corticosteroids as adrenocortical suppressants for the treatment of recurrent and metastatic mammary carcinoma. He has now provided data in another study which support the view that corticosteroid therapy should be considered in addition to castration for the prophylaxis of recurrent mammary carcinoma. There is no necessity to be unduly timid about such a proposal when somewhat similar treatment is being widely used in the long-term management of conditions such as asthma, where the prognosis is not so gloomy. In any case we now have an adequate knowledge of the risks involved in treatment of this type, and should know how to deal with these hazards.
Clinical Trials of Hormone Therapy
In the treatment of recurrent disease, it is surprising that few serious attempts appear to have been made to compare the value of suppressive treatment with corticosteroids and the other methods now in use, such as adrenalectomy, hypo-physectomy, and treatment with androgens and their analogues. Dao et al. (1961) claimed a remission rate of 44 % for adrenalectomy compared with nil for cortisone in one such trial, but the situation is probably not so unfavourable as this implies. Further trials of this and other methods are still needed, and the disease is so common that it should be possible to make effective comparisons rapidly. In this regard, a remarkable example is provided by the work of the Cancer Chemotherapy National Service Centre of the National Institutes of Health in the U.S.A. They have taken advantage of the technique of double-blind trials developed in this country, and have concentrated on androgen analogues, but they are now applying the method to systematic studies with oestrogens (Segaloff 1962) . For the androgen trials, they used testosterone propionate as the reference standard, and compared the analogues with this. Of these analogues, one of the most promising was 2a methyldihydrotestosterone. In 1959 Blackburn & Childs reported regressions in 12 of 27 patients treated with this steroid, but further studies extending to 98 patients showed that a remission could only be claimed in 26% of the patients treated compared with 25 % of the other 87 patients in this double-blind trial who were treated with testosterone propionate (Blackburn 1962 ). This new analogue did, however, appear to have the advantage of being less androgenic and therefore more tolerable for prolonged treatment.
Carter (1962) has recently summarized the experience of the Co-operative Breast Cancer Group with testosterone propionate as a regression rate of 21 % in a total of 564 postmenopausal patients treated, none of whom had previously been given hormones. This is not encouraging and indeed compares unfavourably with almost every other method of treatment at present in use.
In this country a model study designed to compare the value of adrenalectomy and hypophysectomy in the management of advanced breast cancer was described by Atkins et al. (1960) , and this work must now be well known to all who are concerned with breast cancer. The findings have not been confirmed by the Joint Committee of the American Colleges of Physicians and Surgeons (Macdonald 1962) who could find no advantage for either procedure over the other. This conclusion, based as it is on nearly 1,200 patients, is perhaps an indictment of clinical investigation by committee, rather than of the work of the Guy's Hospital group.
Predicting the Response to Hormone Therapy The search for a method of predicting the response to hormone therapy in mammary carcinoma has been pressed by many investigators (Bulbrook & Strong 1960) . Bulbrook et al. (1962) have described promising studies of this type.
From the technical point of view, the methods employed are not yet suitable for general use, and the results of the steroid hormone assays used do not by themselves provide a clearly defined dividing line between those patients who will respond to adrenalectomy or hypophysectomy or to neither. The work, however, provides a point of entry into what should be a most rewarding field of study. Already it is clear that age is an important factor in modifying the results obtained and, for reasons that I shall discuss, thyroid function and the nutritional status of the patient may also need to be taken into account. Basically, the conclusions depend on changes in the ratio between urinary l11-deoxy 17-oxosteroids, that is, dehydroepiandrosterone, androsterone and wtiocholanolone on the one hand, and the 1 7-hydroxycorticosteroids, largely derived from cortisol, on the other.
Factors Affecting Steroid Metabolism
It is known that one factor determining cortisol production rates is body weight (Mlynaryk et al. 1962) , and a number of studies have been published to show that 1 7-hydroxycorticosteroid output is increased in obesity (e.g. Simkin 1961 ). Hellman et al. (1961) have demonstrated that both the form in which corticosteroids circulate and the amount produced are influenced by the concentration of thyroid hormone in the circulation.
They have also shown that the amount and proportions of androsterone and aetiocholanolone excreted can be altered in the same way (Hellman et al. 1959 ). Our own investigations in patients with recurrent carcinoma have shown that their thyroid function may vary between hyperthyroid and hypothyroid levels, and their weights also vary over a very wide range. For example, in one group of 38 patients body weight ranged from 40 to 96 kg with a mean of 65-7 kg and a standard deviation of 13 4 kg. Knowing that these two factors can vary so much, and recognizing their impact on steroid output, complicated further by the influence of variations in age, it is perhaps surprising that it has been possible to obtain even such good correlations with the disease as those described by Bulbrook et al. (1962) . In discussing the significance of their findings, these authors suggested that since their assays represent excretion products of adrenal androgen production, the latter may be important in relation to breast cancer in so far as they might be coupled with normal or abnormal cestrogen production, and in this way modify the biological activity of the estrogens in the circulation. Exhaustive studies have been carried out on cestrogen metabolism in this disease (Bulbrook & Strong 1960 ) but, bearing in mind the limitations of the methods used for this purpose, it is apparent that no definite conclusions, except in a negative sense, have yet emerged. In my view the problem will be ready for further study when more comprehensive methods are available which take into account variations in metabolism due to physiological factors such as age, nutrition, and thyroid function. Meanwhile our own studies (Brown & Strong 1962) of oestrogen metabolism in patients free of cancer have shown striking relationships between the proportions of oestrone and cestriol recovered in the urine after the administration of oestradiol by injection, the ratio cestriol/oestrone being greater in the obese than in the lean, and when similar comparisons were made in hyperthyroid and hypothyroid patients, the ratio was found to be greater in the hypothyroid.
The Use of Thyroid Hormone A number of workers have claimed that the addition of thyroid hormone to the treatment of patients with steroid hormones or by other methods would improve the results obtained. Emery & Trotter (1963) have recently reported on a double-blind trial which showed conclusively that triiodothyronine in doses up to 120 pg daily did not influence the course of the disease, but in this study the thyroid hormone was given by itself for the duration of the investigation. Stoll (1962) has described the failure of thyroid extract and triiodothyronine to affect the response to treatment when combined with synthetic cestrogens. Gardner et al. (1962) on the other hand claimed a remission rate of 24 % in 46 postmenopausal patients treated with prednisone and triiodothyronine. The average duration of the remission was six months (range one to fifteen months), and on the high doses of steroid used (prednisone 10 mg eight-hourly) it was not surprising that most of the patients developed signs of Cushing's syndrome. This study was carried out on patients who had been treated previously with androgen analogues, and in that restricted sense could have been said to be hormone unresponsive. On the other hand, the design of the study does not make it clear how the triiodothyronine contributed to this result. However, in view of recent work on the effect of thyroid hormone on the metabolism of corticosteroids, androgens and oestrogens, we should perhaps be cautious about lightly discarding this factor as one of no consequence.
Other Studies on Hormone Responsiveness
Some other attempts to predict the response to hormone therapy are summarized in Table 1 . Gonadotrophin assays (Loraine et al. 1957 ) gave some indication, based on probability rather than a clear separation of clinical groups, of the patients who should not be treated with (estrogens. Kushinsky et al. (1960) , in a preliminary report, suggested that patients who respond favourably to treatment with stilbcestrol resemble normal women and women with benign breast disease in excreting a higher proportion of administered aestradiol as cestrone compared with cestriol. This category would correspond to our hyperthyroid patients. Shucksmith et al. (1960) proposed two studies which they claimed provided a method of predicting the results in approximately 80% of 18 cases submitted to adrenalectomy or hypophysectomy, and in 4 of 5 cases who were treated by hypophysectomy after adrenalectomy. The method consisted of urinary cestrogen assays combined with a histological assessment of the state of lobular development in the normal breast.
While investigating the uptake of tritiated hexoestrol by tumour tissue before treatment, Folca et al. (1961) found that in patients whose tumours regressed after adrenalectomy, the uptake ofradioactive hexoestrol was greater than in those tumours which failed to respond to this operation.
McCalister & Welbourn (1962) studied a group of 10 patients before hypophysectomy, and found 
Ovine prolactin
Hypophysectomy Increase in urine calcium by patients with responsive tumours that those patients who subsequently responded favourably to hypophysectomy excreted more urinary calcium during treatment with ovine prolactin than the patients who failed to respond. Much energy and thought have been devoted to these and other tests for the prediction of the response to treatment in mammary carcinoma. For the time being we must accept the fact that certain tumours are not hormone responsive, and realize that with those that are, the rewards of quite formidable operations are usually short lived. A fresh approach to the problem would be welcome.
CANCER OF THE PROSTATE
Cancer of the prostate is a lesser problem in some ways than breast cancer, partly because the age of onset is usually later and, in general, the disease is more readily controlled, usually by the administration of cestrogens, with or without orchidectomy, and occasionally with the addition of local surgery when required to relieve obstructive symptoms. Fergusson (1963) discussed these and many other aspects of the disease. He reserves orchidectomyfor caseswhere he is uncertain that the patient has been taking or is able to take the cestrogen therapy prescribed. He emphasized the importance of not accepting failure lightly, and the necessity for considering measures other than castration and cestrogen therapy when these fail or the disease escapes from control by either or both of these measures. Having had a considerable measure of success with pituitary ablation by implantation of radioactive sources, he prefers this method to adrenalectomy, either surgical or 'medical', or to hypophysectomy by open operation, though each of these in other studies has been shown to be of some value.
Pituitary Suppressants
Our present concept of the behaviour of this disease relates activity of the tumour to a continued supply of testicular or adrenal androgen, this in turn depending on an appropriate pituitary gonadotrophic stimulus. Oestrogens may suppress pituitary gonadotrophin secretion, and may also act as direct antagonists to tumour growth. We (Tulloch & Strong 1962, unpublished (Paget et al. 1961 ) to be a potent inhibitor of pituitary gonadotrophin secretion in animals, and it reduces the excretion of urinary gonadotrophins in postmenopausal women (Bell et al. 1962a ). It might therefore be considered worthy of a trial in mammary carcinoma occurring in postmenopausal patients, and judging by the inhibition of ovarian function described by Bell et al. (1962b) , it might also be expected to be of value in premenopausal patients. There are, however, more reliable methods of ovarian inhibition such as oophorectomy and ovarian irradiation, but these of course are irreversible; this is no disadvantage when dealing with mammary carcinoma.
Corticosteroid Therapy
In view of the early research on prostatic carcinoma showing the close association between androgen metabolism and the activity of the tumour, it is surprising that so few studies have been made on hormone excretion or metabolism in this disease, and how little notice appears to have been taken of the published results of assays of this type. Birke et al. (1954) compared the effect of high (30 mg) and low (5 mg) daily doses of stilbcestrol on urinary androgen excretion, and showed that the larger dose was approximately twice as effective in reducing the output of 17oxosteroids, androsterone and etiocholanolone.
They were also able to show that cortisone administration after orchidectomy abolished the excretion of these two androgen metabolites in 9 cases out of 10 studied. In the type of elderly man in whom prostatic cancer most commonly presents, adrenalectomy or hypophysectomy by open operation represents a formidable undertaking for a limited reward in terms of extension of useful life in comfort. A serious attempt should be made therefore to assess the value of treatment with corticosteroids, when cestrogens, with or without orchidectomy, have failed. Bulbrook et al. (1959) showed how steroid output falls after castration and after initiating treatment with stilbcestrol, only to increase again gradually in succeeding weeks and months. These observations, along with those of Birke et al. (1954) , offer the prospect of worth-while results with corticosteroid treatment when this is superimposed on the preceding treatment (Fergusson 1963 , Grayhack 1959 .
CANCER OF THE THYROID
The necessity fortreating cancer of the thyroid with adequate suppressive therapy is now widely accepted, though it is difficult to find substantial evidence regarding the incidence of responsive tumours. Smithers (1959) reviewed the problem recently, and Crile (1960) has emphasized the necessity for treating all thyroid cancers with thyroid hormone after conventional surgical measures. Crile (1960) incidentally gave a warning of the danger of converting a relatively inactive follicular or papillary thyroid carcinoma into a rapidly progressive anaplastic type of tumour by treatment with radioiodine. It seems likely that treatment with thyroid hormone has inevitably been widely used for a long time, simply as replacement therapy for patients who have been treated by total or subtotal thyroidectomy, and the successes claimed in the past for surgery and radiotherapy may have been due in part to this simple measure. In view of the occasional failure of thyroid extract to provide effective replacement therapy, L-thyroxine should now always be used in full doses, that is, the maximum amount tolerated. Where facilities for making the estimation are available, the serum protein-bound iodine concentration should be maintained in the range of 6-8 ,ug/l00 ml, so that the output of pituitary thyrotrophic hormone is suppressed as completely as possible. A tracer radioiodine uptake test from time to time would provide some confirmation that suppression is indeed effective. Recent developments in methods for the assay of thyroid stimulating hormone in body fluids should soon make it possible to obtain reliable information about pituitary activity in this disease, so that we shall be able to recognize hormone responsiveness in these tumours by more direct methods than are possible at present.
CANCER OF THE UTERUS
Finally, some brief reference should be made to the use of progestational compounds in the management of cancer of the uterus. Numerous additions have recently been made to the choice of synthetic compounds available, of which progesterone may be regarded as the natural counterpart. Kelley & Baker (1961) , for example, have claimed objective remissions lasting between nine and fifty-four months in 6 of 21 patients with endometrial carcinoma previously treated either surgically or with radiotherapy or by both, and they stated that regression of pulmonary metastases occurred in 5 of 6 patients. Since these findings compare favourably with the results of hormone therapy in, for example, breast cancer, they must be regarded as meriting a more extended trial. DISCUSSION Mr Anthony Green (Royal Northern Hospital, London) said that a 'new clinic' for hormone control of breast cancer had been established with a marked improvement in results.
Each patient's 'aestrogen state' was classified into one of two main categories by means of vaginal smears taken by the nursing staff three times per week for one month. The smear count was graphically recorded. 'High cestrogens' were suppressed and very low were given stilbeestrol. ACTH was given and 17-hydroxycorticoids in the urine estimated. High figures suggested the advisability of adrenal suppression with prednisolone.
The objective remission rate at six months exceeded 60% and was still improving; mainly nonsurgical methods were used in an unselected series. Several hormones and suppressant agents were in use. Best survivals exceeded five years of normal life.
A method of clinical recording ensuring that none was lost to follow-up was shown. Each patient had a horizontal line on a record board so that progress could be indicated by fixing adhesive colour discs along that line: e.g. red= active disease or patient not well; green = objective remission andpatient well (60 % +).
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